Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers

Drug Metabolism and Disposition

Volumn 31, Issue 2, 2003, Pages 224-232

  Rodrigues, A David ^a   Halpin, Rita A ^a   Geer, Leslie A ^a   Cui, Donghui ^a   Woolf, Eric J ^a   Matthews, Catherine Z ^a   Gottesdiener, Keith M ^a   Larson, Patrick J ^a   Lasseter, Kenneth C ^b   Agrawal, Nancy G B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Clinical Pharmacology Associates Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB;

ARTICLE; BIOAVAILABILITY; DERIVATIZATION; DRUG ABSORPTION; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; PRIORITY JOURNAL; RADIOCHROMATOGRAPHY;

ANALYSIS OF VARIANCE; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FECES; HUMANS; INTESTINAL ABSORPTION; ISOENZYMES; MALE; MEMBRANE PROTEINS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; SULFONES;

EID: 12244293400     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.31.2.224     Document Type: Article

References (21)

1. Agrawal NGB, Matthews CZ, Rose MJ, Woolf EJ, Porras AG, Mazina KE, Farmer J, Musser BJ, Dynder AL, Lasseter KC, et al. (2002) Single- and multiple-dose pharmacokinetics of etoricoxib, a highly selective inhibitor of cyclooxygenase-2, in healthy subjects [Abstract]. Clin Pharmacol Ther 71:50.
2. Agrawal NGB, Porras AG, Matthews CZ, Woolf EJ, Miller JL, Mukhopadhyay S, Neu DC, and Gottesdiener KM (2001) Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 41:1106-1110.
3. Chauret N, Yergey JA, Brideau C. Friesen RW, Mancini J, Riendeau D, Scheigetz J, Silva J, Styhler A, Trimble L, and Nicoll-Griffith D (2001) In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663). Bioorg Med Chem Lett 11:1059-1062.
4. Davies B and Morris T (1993) Physiological parameters in laboratory animals and man. Pharm Res (NY) 10:1093-1095.
5. Donnelly MT and Hawkey CJ (1997) COX-II inhibitors-a new generation of safer NSAIDs? Aliment Pharmacol Ther 11:227-236.
6. Garnett WR (2001) Clinical implications of drug interactions with coxibs. Pharmacotherapy 21:1223-1232.
7. Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, et al. (2002) The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab Dispos 30:684-693.
8. Jouzeau J-Y, Terlain B, Abid A, Nedelec E, and Netter P (1997) Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs. Drugs 53:563-582.
9. Karim A, Laurent A, Slater ME, Kuss ME, Qian J, Crosby-Sessoms SL, and Hubbard RC (2001) A pharmacokinetic study of intramuscular (IM) parecoxib sodium in normal subjects. J Clin Pharmacol 41:1111-1119.
10. Kassahun K, McIntosh I, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, Geer LA, Halpin RA, Agrawal N, and Rodngues AD (2001) Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 29:813-820.
11. Lane NE (1997) Pain management in osteoarthritis: the role of COX-2 inhibitors. J Rheumatol 24:20-24.
12. Lipsky PE and Isakson PC (1997) Outcome of specific COX-2 inhibition in rheumatoid arthritis. J Rheumatol 24:9-14.
13. Matthews CZ, Woolf EJ, Lin L, Fang W, Hsieh J, Ha S, Simpson R, and Matuszewski BK (2001) High-throughput, semi-automated determination of a cyclooxygenase II inhibitor in human plasma and urine using solid-phase extraction in the 96-well format and high-performance liquid chromatography with post-column photochemical derivatization-fluorescence detection. J Chromatogr B Biomed Sci Appl 751:237-246.
14. Ouellet M, Riendeau D, and Percival MD (2001) A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-I inactivation by aspirin. Proc Natl Acad Sci USA 98:14583-14588.
15. 14C] celecoxib in healthy male volunteers. Drug Metab Dispos 28:308-314.
16. Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, et al. (2001) Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296:558-566.
17. Sorbera LA, Castaner RM, Silvestre J, and Castaner J (2001) Etoricoxib: analgesic drug, antiarthritic, cyclooxygenase-2 inhibitor. Drugs Future 26:346-353.
18. Tang C, Shou M, Mei Q, Rushmore TH, and Rodrigues AD (2000) Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 293:453-459.
19. Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, et al. (2001) In vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in vivo pharmacokinetics. Pharmacogenetics 11:223-235.
20. Yeh KC and Remphrey K (1990) A simplex optimization program. Pharm Res (NY) 7:S244.
21. Yuan JJ, Yang DC, Zhang JY, Bible R, Karim A, and Finlay JW (2002) Disposition of a specific cyclooxygenase inhibitor, valdecoxib, in human. Drug Metab Dispos 30:1013-1021.